Total Payments
$57,729
2024 Payments
$7,774
Companies
63
Transactions
713
Medicare Patients
4,910
Medicare Billing
$214,239
Payment Breakdown by Category
Research$36,219 (62.7%)
Food & Beverage$11,214 (19.4%)
Travel$4,235 (7.3%)
Other$3,200 (5.5%)
Consulting$2,200 (3.8%)
Education$640.09 (1.1%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36,219 | 38 | 62.7% |
| Food and Beverage | $11,214 | 652 | 19.4% |
| Travel and Lodging | $4,235 | 16 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 1 | 5.5% |
| Consulting Fee | $2,200 | 2 | 3.8% |
| Education | $640.09 | 3 | 1.1% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$36,219
38 transactions
General
$21,509
675 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $30,198 | 80 | $0 (2024) |
| SANOFI PASTEUR INC. | $8,131 | 19 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,933 | 37 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,541 | 41 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $1,378 | 5 | $0 (2021) |
| DENTSPLY IH Inc. | $1,048 | 2 | $0 (2017) |
| ABBVIE INC. | $895.94 | 53 | $0 (2024) |
| Lilly USA, LLC | $790.57 | 49 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $704.97 | 40 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $546.08 | 35 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,774 | 97 | PFIZER INC. ($3,247) |
| 2023 | $5,223 | 87 | PFIZER INC. ($2,780) |
| 2022 | $6,130 | 87 | PFIZER INC. ($4,600) |
| 2021 | $10,055 | 74 | PFIZER INC. ($7,710) |
| 2020 | $9,217 | 71 | PFIZER INC. ($4,489) |
| 2019 | $2,156 | 91 | Merck Sharp & Dohme Corporation ($1,258) |
| 2018 | $10,503 | 100 | PFIZER INC. ($6,093) |
| 2017 | $6,671 | 106 | GlaxoSmithKline, LLC. ($2,426) |
All Payment Transactions
713 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: DIABETES | ||||||
| 12/20/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: HIV | ||||||
| 12/19/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $28.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/19/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $26.80 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/13/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $1,250.00 | Research |
| Study: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $185.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $889.43 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $123.54 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological), PEDIARIX | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: VACCINES | ||||||
| 11/25/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Biological | ||||||
| 11/15/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: HIV | ||||||
| 11/11/2024 | Organon Llc | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $10.01 | General |
| Category: ETONOGESTREL | ||||||
| 11/07/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: PAIN | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological), PEDIARIX | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: VACCINES | ||||||
| 10/11/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Biological | ||||||
| 10/02/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: VACCINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MENINGOCOCCAL VACCINE B RFHBPAFHBPB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,870 | 4 |
| MENINGOCOCCAL B CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,740 | 5 |
| Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine | SANOFI PASTEUR INC. | $3,740 | 1 |
| C DIFF VACCINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| RESPIRATORY SYNCYTIAL VIRUS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | SANOFI PASTEUR INC. | $2,500 | 2 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $1,754 | 8 |
| MENINGOCOCCAL VACCINES CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| ZOSTER 048 | GlaxoSmithKline, LLC. | $1,371 | 1 |
| A Phase 3b, Controlled, Open Label, Multi Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline s Meningococcal ACWY Conjugate Vaccine Menveo , Administered to Healthy Individuals 15 through 55 years of age, approximate | GlaxoSmithKline, LLC. | $1,031 | 9 |
| ZOSTER-048 | GlaxoSmithKline, LLC. | $676.37 | 1 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI US SERVICES INC. | $54.80 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,149 | 1,446 | $126,819 | $57,461 |
| 2022 | 25 | 1,106 | 1,357 | $105,324 | $47,794 |
| 2021 | 29 | 1,208 | 1,462 | $113,101 | $50,486 |
| 2020 | 25 | 1,447 | 1,695 | $147,157 | $58,498 |
Total Patients
4,910
Total Services
5,960
Medicare Billing
$214,239
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 189 | $31,185 | $14,616 | 46.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 76 | 76 | $15,200 | $9,315 | 61.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 172 | $18,060 | $9,223 | 51.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 15 | 15 | $4,200 | $4,083 | 97.2% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 30 | 30 | $8,850 | $3,726 | 42.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 42 | 42 | $3,360 | $3,021 | 89.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 101 | 116 | $9,048 | $1,909 | 21.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 102 | 132 | $6,336 | $1,356 | 21.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 46 | 46 | $1,472 | $1,349 | 91.7% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 91 | 98 | $7,252 | $1,286 | 17.7% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 30 | 30 | $1,200 | $1,134 | 94.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 23 | 29 | $3,567 | $1,040 | 29.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 71 | 91 | $2,366 | $849.07 | 35.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 89 | 112 | $2,800 | $844.71 | 30.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 18 | 18 | $2,700 | $639.18 | 23.7% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 13 | 13 | $520.00 | $508.30 | 97.8% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 25 | 25 | $2,075 | $473.00 | 22.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 15 | 15 | $480.00 | $439.95 | 91.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 32 | $1,280 | $308.85 | 24.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 11 | 12 | $972.00 | $277.64 | 28.6% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2023 | 12 | 12 | $432.00 | $212.28 | 49.1% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 12 | 13 | $403.00 | $192.14 | 47.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 19 | 23 | $460.00 | $185.30 | 40.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 13 | 14 | $350.00 | $173.68 | 49.6% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 30 | 43 | $731.00 | $133.73 | 18.3% |
About Dr. James Peterson, MD
Dr. James Peterson, MD is a Family Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316962442.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Peterson, MD has received a total of $57,729 in payments from pharmaceutical and medical device companies, with $7,774 received in 2024. These payments were reported across 713 transactions from 63 companies. The most common payment nature is "" ($36,219).
As a Medicare-enrolled provider, Peterson has provided services to 4,910 Medicare beneficiaries, totaling 5,960 services with total Medicare billing of $214,239. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Other Specialties Obstetrics
- Location Salt Lake City, UT
- Active Since 07/12/2006
- Last Updated 09/11/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1316962442
Products in Payments
- TRUMENBA (Biological) $13,021
- MENQUADFI (Biological) $3,740
- V114 (Biological) $2,223
- NURTEC ODT (Drug) $1,565
- PREVNAR - 13 (Biological) $1,488
- Implant Dentistry (Device) $1,048
- UBRELVY (Drug) $559.58
- APRETUDE (Biological) $436.77
- JARDIANCE (Drug) $358.03
- FARXIGA (Drug) $354.67
- Kerendia (Drug) $345.43
- TRADJENTA (Drug) $323.43
- VRAYLAR (Drug) $309.91
- Vascepa (Drug) $256.92
- Aimovig (Biological) $238.61
- TRULICITY (Drug) $227.61
- MOUNJARO (Drug) $218.45
- VOQUEZNA (Drug) $216.59
- Ozempic (Drug) $213.93
- SHINGRIX (Biological) $191.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Salt Lake City
Dr. David Larsen, Md, MD
Family Medicine — Payments: $95,550
Family Medicine $95,550
Mark Cacciamani, Md, MD
Family Medicine — Payments: $42,635
Family Medicine $42,635
Shane Christensen, M.d, M.D
Family Medicine — Payments: $22,787
Family Medicine $22,787
Dr. Derek Muse, M.d, M.D
Family Medicine — Payments: $22,657
Family Medicine $22,657
Jared Probst, Md, MD
Family Medicine — Payments: $18,582
Family Medicine $18,582
Dr. Mara Rabin, M.d, M.D
Family Medicine — Payments: $14,713
Family Medicine $14,713